News coverage about Genocea Biosciences (NASDAQ:GNCA) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Genocea Biosciences earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 48.1206137935027 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences … – Nasdaq (nasdaq.com)
- Genocea Biosciences, Inc. (NASDAQ:GNCA) – Hot Stock’s Highlights – Nasdaq Journal (nasdaqjournal.com)
- Traders Alert on Unusual Volume Genocea Biosciences, Inc. (GNCA) – Wall Street Morning (wallstreetmorning.com)
- Genocea Biosciences, Inc., (NASDAQ: GNCA) – Average True Range (ATR) to Consider – Stock Watch (stocksnewstimes.com)
- Analysts Watch-List Stock: Genocea Biosciences, Inc. (GNCA) – Wall Street Morning (wallstreetmorning.com)
Genocea Biosciences (GNCA) remained flat at $$1.15 during mid-day trading on Thursday. 192,550 shares of the company’s stock traded hands, compared to its average volume of 1,245,309. The company has a current ratio of 0.83, a quick ratio of 0.83 and a debt-to-equity ratio of -1.26. The stock has a market cap of $96.88, a PE ratio of -0.58 and a beta of 1.31. Genocea Biosciences has a 52-week low of $0.79 and a 52-week high of $7.29.
Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Friday, February 16th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.03. research analysts anticipate that Genocea Biosciences will post -0.55 earnings per share for the current fiscal year.
Several equities analysts have recently commented on GNCA shares. Zacks Investment Research lowered Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Needham & Company LLC raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research note on Tuesday, February 6th. Robert W. Baird started coverage on Genocea Biosciences in a research note on Monday, February 12th. They issued an “outperform” rating and a $3.00 price target on the stock. Cantor Fitzgerald started coverage on Genocea Biosciences in a research note on Monday, March 5th. They issued an “overweight” rating and a $5.00 price target on the stock. Finally, HC Wainwright started coverage on Genocea Biosciences in a research note on Thursday, March 8th. They issued a “buy” rating and a $5.00 price target on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $4.41.
COPYRIGHT VIOLATION WARNING: “Genocea Biosciences (GNCA) Earns News Sentiment Score of 0.16” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.thelincolnianonline.com/2018/03/15/genocea-biosciences-gnca-earns-news-sentiment-score-of-0-16.html.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.